Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**4-(Acetylamino)-3-Guanidinobenzoic Acid** is a synthetic small molecule compound with the chemical formula C10H14N4O3 and a molecular weight of approximately 238.24 g/mol[1][2][6]. It features a benzoic acid backbone substituted with an acetylamino group at the para (4-) position and a guanidino group at the meta (3-) position[2][6]. The compound has been investigated as an experimental agent, notably in structure-based drug design efforts targeting influenza neuraminidase, suggesting potential antiviral activity through inhibition of this viral enzyme[7]. However, it has not been approved for any clinical use or indication to date and remains primarily of research interest.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 4-(acetylamino)-3-guanidinobenzoic acid.